All-cause mortality | Crude HR (95% CIs) | Adjusted HR (95% CIs)* | ||||
---|---|---|---|---|---|---|
Model 1 | Model 2 | |||||
Patients with intact AAA treated by EVAR or OSR (n = 11,785) | ||||||
30-day mortality | 2.93 | (1.37–6.28) | 2.98 | (1.39–6.41) | 2.97 | (1.38–6.39) |
90-day mortality | 2.33 | (1.37–3.99) | 2.24 | (1.31–3.84) | 2.27 | (1.33–3.89) |
Total mortality | 2.07 | (1.62–2.65) | 1.90 | (1.49–2.43) | 1.95 | (1.52–2.49) |
Patients with intact AAA treated by EVAR (n = 7903) | ||||||
30-day mortality | 2.85 | (1.15–7.03) | 3.05 | (1.23–7.58) | 3.04 | (1.22–7.58) |
90-day mortality | 1.84 | (0.94–3.58) | 1.84 | (0.94–3.58) | 1.90 | (0.97–3.71) |
Total mortality | 1.91 | (1.44–2.54) | 1.77 | (1.33–2.36) | 1.81 | (1.36–2.41) |
Patients with intact AAA treated by OSR (n = 3882) | ||||||
30-day mortality | 3.26 | (0.79–13.47) | 3.08 | (0.74–12.79) | 3.26 | (0.78–13.67) |
90-day mortality | 4.09 | (1.66–10.07) | 3.57 | (1.44–8.83) | 3.69 | (1.48–9.19) |
Total mortality | 2.33 | (1.44–3.77) | 2.25 | (1.39–3.64) | 2.29 | (1.41–3.71) |